Non-Alkolik Steatoz Hastalarında Karaciğer Enzim Düzeylerinin ve İnsülin Direncinin Korelasyonu

Yıl 2019, , 123 - 132, 22.03.2019

Demet Cekdemir , Mehmet Gunduz Arzu Celebi Hale Aslantas Gokhan Pekındıl Semin Ayhan Ender Ellidokuz

https://doi.org/10.17098/amj.542200

Öz

Amaç: Non-alkolik basit hepatik steatoz
hastalarını karaciğer enzim düzeylerine göre karşılaştırmak ve glikoz
metabolizması ve insülin direncinin karaciğer enzim düzeyleri ile farklılık
gösterip göstermediğini saptamak.

Materyal ve Metot: Çalışmaya 18-65 yaş
arası non-alkolik basit hepatik steatozu olan hastalar dahil edildi. Hastalar
normal karaciğer enzimleri (NKE) ve artmış karaciğer enzimleri (AKE) olan
hastalar olarak iki gruba ayrıldı. Gruplar, glukoz metabolizması parametreleri
ve insülin direnci açısından karşılaştırıldı.

Bulgular: Çalışmamıza toplam 66
steatotik hasta (40 NKE ve 26 AKE) dahil edildi. NKE ve AKE gruplarında ortalama
insülin değerleri sırasıyla 12,92 ± 5,61 ve 16,22 ± 5,43 μU / mL idi (p =
0,012). NKE'deki 23 (%60,50) hastada ve steatotik AKE grubunda 22 hastada (%88)
insülin direnci saptandı (p = 0,018). NKE'de 31 (%77,50) hastada ve AKE
grubunda 15 hastada (%57,70) metabolik sendrom saptandı (p = 0,058).

Sonuç: Sonuç olarak, AKE'li steatotik grubun
insülin direncinin daha yüksek olduğu sonucuna vardık. Bu hastalar özellikle
insülin direncini azaltacak hem kilo kaybını artıracak hem de insülin direncine
duyarlı olacak ilaç tedavileri konusunda titiz bir şekilde dikkate alınmalıdır.
Karaciğer biyopsisi, kesin ayırıcı tanıda gerekli yerini hala korumaktadır.

Anahtar Kelimeler

Non-alkolik basit hepatik steatoz, basit hepatik steatoz, insülin direnci

Correlation of Liver Enzyme Levels and Insulin Resistance in Patients with Non-Alcoholic Steatosis

Öz

Objectives: To compare non-alcoholic steatosis patients according to liver enzyme
levels, and to establish whether glucose metabolism and insulin resistance
differ with liver enzyme levels.

Materials and Methods: Patients with
non-alcoholic steatosis aged between 18-65 years were included in this study.
The patients were divided into two groups as steatotic patients with normal
liver enzymes (NLE), and those with increased liver enzymes (ILE). The groups
were compared as for parameters of glucose metabolism, and insulin resistance.

Results: A total of 66 steatotic
patients (40 NLE, and 26 ILE) were included in our study. Mean insulin values
in the steatotic NLE, and ILE groups were 12.92±5.61, and 16.22±5.43 μU/mL
respectively (p=0.012). Insulin resistance was detected in 23 (60.50%) patients
in the steatotic NLE, and in 22 (88%) patients in the steatotic ILE groups
(p=0.018). Metabolic syndrome was detected in 31 (77.50%) patients in the
steatotic NLE, and in 15 (57.70%) patients in the steatotic ILE groups
(p=0.058).

Conclusion: In conclusion, we have
concluded that the steatotic group with ILE had higher insulin resistance. These
patients should be meticulously taken into consideration as for drug treatments
which will especially decrease insulin resistance, increase both weight loss,
and sensitivity to insulin resistance. Liver biopsy still retains its essential
place in definitive differential diagnosis.

Anahtar Kelimeler

Non-alcoholic fatty liver disease, fatty liver, insulin resistance

Kaynakça

• Cortez-Pinto H, Camilo ME. Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): diagnosis and clinical course. Best Pract Res Clin Gastroenterol 2004;18:1089-104.
• Demir M, Deyneli O, Yılmaz Y. Screening for hepatic fibrosis and steatosis in Turkish patients with type 2 diabetes mellitus: A transient elastography study. Turk J Gastroenterol. 2018 Nov 9. doi: 10.5152/tjg.2018.18559. [Epub ahead of print]
• Bugianesi E, Gentilcore E, Manini R, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005;100:1082-90.
• Açikel M, Sunay S, Koplay M, Gündoğdu F, Karakelleoğlu S. Evaluation of ultrasonographic fatty liver and severity of coronary atherosclerosis, and obesity in patients undergoing coronary angiography. Anadolu Kardiyol Derg. 2009;9(4):273-9.
• Goren B, Fen T. Non-alcoholic fatty liver disease: review. Turkiye Klinikleri J Med Sci 2005, 25:84 1-850.
• Tankurt E, Biberoglu S, Ellidokuz E, et al. Hyperinsulinemia and insulin resistance in non-alcoholic steatohepatitis. J Hepatol 1999;31:963.
• Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003;37:1286-92.
• Neuschwander-Tetri BA. Fatty liver and the metabolic syndrome. Curr Opin Gastroenterol 2007;23:193-8.
• Ahmed MH, Byrne CD. Nonalcoholic steatohepatitis. In: byrne CD, Wild S, eds. Metabolic Syndrome 2005:279-303.
• Marceau P, Biron S, Hould FS, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999;84:1513-7.
• Luyckx FH, Desaive C, Thiry A, et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 1998;22:222-6.
• Haukeland JW, Konopski Z, Linnestad P, et al. Abnormal glucose tolerance is a predictor of steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease. Scand J Gastroenterol 2005;40:1469-77.
• Ikai E, Ishizaki M, Suzuki Y, Ishida M, Noborizaka Y, Yamada Y. Association between hepatic steatosis, insulin resistance and hyperinsulinaemia as related to hypertension in alcohol consumers and obese people. J Hum Hypertens 1995;9:101-5.
• Santoliquido A, Di Campli C, Miele L, et al. Hepatic steatosis and vascular disease. Eur Rev Med Pharmacol Sci 2005;9:269-71.
• Letteron P, Fromenty B, Terris B, Degott C, Pessayre D. Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice. J Hepatol 1996;24:200-8.
• Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998;27:128-33.
• de la Maza MP, Hirsch S, Petermann M, Suazo M, Ugarte G, Bunout D. Changes in microsomal activity in alcoholism and obesity. Alcohol Clin Exp Res 2000;24:605-10.
• Hasler P, Zouali M. Immune receptor signaling, aging, and autoimmunity. Cell Immunol 2005;233:102-8.
• Fulop T, Larbi A, Wikby A, Mocchegiani E, Hirokawa K, Pawelec G. Dysregulation of T-cell function in the elderly: scientific basis and clinical implications. Drugs Aging 2005;22:589-603.
• van de Wiel A, van Hattum J, Schuurman HJ, Kater L. Immunoglobulin A in the diagnosis of alcoholic liver disease. Gastroenterology 1988;94:457-62.
• Kunimoto DY, Ritzel M, Tsang M. The roles of IL-4, TGF-beta and LPS in IgA switching. Eur Cytokine Netw 1992;3:407-15.
• Malnick SD, Beergabel M, Knobler H. Non-alcoholic fatty liver: a common manifestation of a metabolic disorder. QJM 2003;96:699-709.
• Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001;21:17-26.
• Kumar KS, Malet PF. Nonalcoholic steatohepatitis. Mayo Clin Proc 2000;75:733-9.
• Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006;43:S99-S112.
• Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002;122:1649-57.
• Daniel S, Ben-Menachem T, Vasudevan G, Ma CK, Blumenkehl M. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Am J Gastroenterol 1999;94:3010-4.
• Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990;12:1106-10.
• Silverman JF, O'Brien KF, Long S, et al. Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol 1990;85:1349-55.
• Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 2000;32:689-92.
• Non-alcoholic steatohepatitis; From cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123:134-40. Owerweight FDA. Obesity threaten US health gains. FDA Consum 2002;36:8.